论文部分内容阅读
目的探讨卡培他滨联合奥沙利铂治疗晚期肝癌的有效性。方法根据24例晚期肝癌患者体表面积,采用卡培他滨联合奥沙利铂用药,依照疾病控制情况及WHO实体肿瘤近期疗效评定标准评价。结果治疗后,24例患者中部分缓解(PR)9例(37.50%),病情稳定(SD)10例(41.67%),病情进展(PD)5例(20.83%),有效率(RR)为37.5%,疾病控制率(DCR)为79.17%。研究中患者出现不良反应表现为恶心、呕吐、腹泻等消化道反应,中性粒细胞、血小板减少,外周神经(感觉/运动神经)毒性等,均可逆。结论卡培他滨联合奥沙利铂治疗晚期肝癌的有效率较高,耐受性良好,值得临床推广应用。
Objective To investigate the efficacy of capecitabine combined with oxaliplatin in the treatment of advanced liver cancer. Methods According to the body surface area of 24 patients with advanced liver cancer, capecitabine combined with oxaliplatin was evaluated according to the disease control and the WHO curative effect of solid tumors. Results After treatment, 9 patients (37.50%) had partial remission (PR), 10 (41.67%) had stable disease (SD) and 5 patients (20.83%) had progressive disease (PD). The effective rate 37.5%, and disease control rate (DCR) was 79.17%. In the study, patients showed adverse reactions such as nausea, vomiting, diarrhea and other gastrointestinal reactions, neutrophils, thrombocytopenia, peripheral nerve (sensory / motor nerve) toxicity, are reversible. Conclusion Capecitabine combined with oxaliplatin in the treatment of advanced liver cancer is more effective and well tolerated, which is worthy of clinical application.